By using cell-survival assays with MIA PaCa-2 (KRasG12C), CFPAC-1 (KRasG12V), BxPC-3 (wild-type KRas), Capan-1 (KRasG12V), and SW1990 (KRasG12T), we show that Spiclomazine treatment markedly reduces cell survival in these mutant cancer cell lines. Here, KRAS is linked to cancer.